These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
141 related articles for article (PubMed ID: 28218867)
21. Direct antiviral agents (DAAs) - A new age in the treatment of hepatitis C virus infection. Spengler U Pharmacol Ther; 2018 Mar; 183():118-126. PubMed ID: 29024739 [TBL] [Abstract][Full Text] [Related]
22. Efficacy of interferon based antiviral therapy for recurrent hepatitis C in patients who received steroid free immunosuppression for liver transplantation. Nair S; Lipscomb J; Eason J Transplantation; 2008 Aug; 86(3):418-22. PubMed ID: 18698245 [TBL] [Abstract][Full Text] [Related]
24. Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation. Charlton M; Gane E; Manns MP; Brown RS; Curry MP; Kwo PY; Fontana RJ; Gilroy R; Teperman L; Muir AJ; McHutchison JG; Symonds WT; Brainard D; Kirby B; Dvory-Sobol H; Denning J; Arterburn S; Samuel D; Forns X; Terrault NA Gastroenterology; 2015 Jan; 148(1):108-17. PubMed ID: 25304641 [TBL] [Abstract][Full Text] [Related]
25. [Side-effects of pegylated interferon plus ribavirin therapy with or without protease inhibitor direct acting antiviral agents during treatment of chronic hepatitis C virus infection]. Hunyady B; Kovács B; Battyáni Z Orv Hetil; 2011 Dec; 152(50):1997-2009. PubMed ID: 22112373 [TBL] [Abstract][Full Text] [Related]
26. Achieving sustained virological response: what's the impact on further hepatitis C virus-related disease? van der Meer AJ Expert Rev Gastroenterol Hepatol; 2015 May; 9(5):559-66. PubMed ID: 25579804 [TBL] [Abstract][Full Text] [Related]
27. A review of the treatment of chronic hepatitis C virus infection in cirrhosis. Vezali E; Aghemo A; Colombo M Clin Ther; 2010 Dec; 32(13):2117-38. PubMed ID: 21316532 [TBL] [Abstract][Full Text] [Related]
28. Improved survival of patients with hepatocellular carcinoma and compensated hepatitis C virus-related cirrhosis who attained sustained virological response. Bruno S; Di Marco V; Iavarone M; Roffi L; Boccaccio V; Crosignani A; Cabibbo G; Rossi S; Calvaruso V; Aghemo A; Giacomelli L; Craxì A; Colombo M; Maisonneuve P Liver Int; 2017 Oct; 37(10):1526-1534. PubMed ID: 28418617 [TBL] [Abstract][Full Text] [Related]
29. Immunosuppressive and antiviral treatment of hepatitis C virus-associated glomerular disease: A long-term follow-up. Fabrizi F; Aghemo A; Lampertico P; Fraquelli M; Cresseri D; Moroni G; Passerini P; Donato FM; Messa P Int J Artif Organs; 2018 Jun; 41(6):306-318. PubMed ID: 29595085 [TBL] [Abstract][Full Text] [Related]
30. Sofosbuvir-based treatment of hepatitis C with severe fibrosis (METAVIR F3/F4) after liver transplantation. Dumortier J; Leroy V; Duvoux C; de Ledinghen V; Francoz C; Houssel-Debry P; Radenne S; d'Alteroche L; Fougerou-Leurent C; Canva V; di Martino V; Conti F; Kamar N; Moreno C; Lebray P; Tran A; Besch C; Diallo A; Rohel A; Rossignol E; Abergel A; Botta-Fridlund D; Coilly A; Samuel D; Duclos-Vallée JC; Pageaux GP Liver Transpl; 2016 Oct; 22(10):1367-78. PubMed ID: 27348086 [TBL] [Abstract][Full Text] [Related]
31. [What is expected from the novel triple combination antiviral treatment of patients infected with hepatitis C virus genotype 1?]. Tusnádi A; Szabó A Orv Hetil; 2013 Feb; 154(7):257-61. PubMed ID: 23395789 [TBL] [Abstract][Full Text] [Related]
32. Hepatitis C: epidemiology, diagnosis, natural history and therapy. Pol S; Vallet-Pichard A; Corouge M; Mallet VO Contrib Nephrol; 2012; 176():1-9. PubMed ID: 22310776 [TBL] [Abstract][Full Text] [Related]
34. Advances in the treatment of hepatitis C. Lawrence SP Adv Intern Med; 2000; 45():65-105. PubMed ID: 10635046 [TBL] [Abstract][Full Text] [Related]
35. Evaluation of advanced fibrosis measured by transient elastography after hepatitis C virus protease inhibitor-based triple therapy. Sáez-Royuela F; Linares P; Cervera LA; Almohalla C; Jorquera F; Lorenzo S; García I; Karpman G; Badia E; Vallecillo MA; Moncada A; Calvo S; Olcoz JL; Eur J Gastroenterol Hepatol; 2016 Mar; 28(3):305-12. PubMed ID: 26636405 [TBL] [Abstract][Full Text] [Related]
36. Therapy of chronic hepatitis C virus infection in the era of direct-acting and host-targeting antiviral agents. Conteduca V; Sansonno D; Russi S; Pavone F; Dammacco F J Infect; 2014 Jan; 68(1):1-20. PubMed ID: 24012819 [TBL] [Abstract][Full Text] [Related]
37. Consensus guidelines for the management of hepatitis C infection. Consensus Guidelines Committee for the Management of Hepatitis C Infection Saudi Med J; 2003 Jul; 24 Suppl 2():S99-118. PubMed ID: 25121186 [TBL] [Abstract][Full Text] [Related]
38. [New possibilities on the horizon for the treatment of hepatitis C virus infection: direct-acting antiviral therapy]. Pár A Orv Hetil; 2010 Dec; 151(50):2045-56. PubMed ID: 21126947 [TBL] [Abstract][Full Text] [Related]
39. [Novel methods of hepatitis C treatment and prevention]. Chmielewska AM; Rychłowska M; Król E; Solarz K; Bieńkowska-Szewczyk K Postepy Hig Med Dosw (Online); 2015 Aug; 69():946-63. PubMed ID: 26400881 [TBL] [Abstract][Full Text] [Related]
40. Two patients treated with simeprevir plus pegylated-interferon and ribavirin triple therapy for recurrent hepatitis C after living donor liver transplantation: case report. Kawaoka T; Imamura M; Kan H; Fujino H; Fukuhara T; Kobayashi T; Honda Y; Naeshiro N; Hiramatsu A; Tsuge M; Hayes CN; Kawakami Y; Aikata H; Ochi H; Ishiyama K; Tashiro H; Ohdan H; Chayama K Transplant Proc; 2015 Apr; 47(3):809-14. PubMed ID: 25891736 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]